An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Leslie A. Crews, PhD
Please welcome Leslie Crews, PhD, Assistant Professor of Medicine, Division of Regenerative Medicine at UC San Diego, as the new Co-Leader of the MCC Hematologic Malignancies Research Program, who will join current Co-Leader, Thomas Kipps, MD, PhD. Read Press Release»
|
| Jason Sicklick, MD, FACS
Please welcome Jason Sicklick, MD, FACS, Professor of Surgery at UC San Diego, as the new Co-Leader of the MCC Structural and Functional Genomics Research Program, who will join current Co-Leader, Jill Mesirov, PhD. Read Press Release»
|
|
|
American Association of Cancer Research (AACR) Scientific Achievement Awards and Lectureships: Now Open for Nominations
Several AACR awards and lectureships are now open for nominations, which are due June 30, 2023 and September 15, 2023. Read More»
|
|
|
| DRM Seminar Series
Spatial Analysis of RNA Distribution During Early Mammalian Embryogenesis
Monday, May 8, 2023 from 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Elsy Buitrago Delgado, PhD
Hanna Gray Postdoctoral Fellow
California Institute of Technology
|
|
|
| DRM Seminar Series
Skeletal Muscle in Three Dimensions: Uncovering Connections Across Development
Monday, May 8, 2023 from 4:00 p.m. to 5:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Matthew A. Romero, PhD
A.P. Giannini Postdoctoral Fellow
Ford Foundation Postdoctoral Fellow
University of California President’s Postdoctoral Fellow
University of California, Los Angeles
|
|
|
| Pharmacology Seminar Series
Drug-evoked Neuronal Rewiring Shifts Inhibition and Excitation Balance
Tuesday, May 9, 2023 at 12:00 p.m.
Leichtag Biomedical Research Building, Room 107
Zoom Link
Tija C. Jacob, PhD
Associate Professor of Pharmacology and Chemical Biology
Vice Chair for Graduate Education
Director of the Molecular Pharmacology Graduate Program
University of Pittsburgh, School of Medicine
|
|
|
| Cancer Biology and Signaling Seminar Series
Lung Function as a Sensory Organ in Health Disease
Wednesday, May 17, 2023
Comer Commons - Lunch Provided
Zoom Link
Xin Sun, PhD
Professor, Department of Pediatrics
Department of Cell and Developmental Biology
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
The Science of . . . Podcast Has Launched
In partnership with the Jackie Robinson Family YMCA Teen Center and Cloudcast Media, MCC researchers have been interviewed by teens for The Science of . . . Cancer podcast, which you can listen to on Spotify, iHeartRadio, or wherever you follow podcasts.
Available Now
Dr. Ezra Cohen: What Is Cancer?
Upcoming Episodes
Dr. Laura Crotty Alexander: What's the Deal with Vaping and Tobacco?
Dr. Angelique Richardson: Communities Fighting Cancer
Dr. Jesse Nodora: Health Literacy, Health Promotion, and How to Get Involved
|
| |
Help Celebrate Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month
You are invited to participate in AANHPI Heritage Month to help celebrate the work and perspectives of MCC Members and UC San Diego Health Sciences colleagues (researchers and staff) who identify as AANHPI. To participate, please email the information below to Maritza Gomez at mag075@health.ucsd.edu.
|
- Name and credentials
- Picture (the higher the resolution the better)
- One to two sentences about what you research and/or your role at MCC
- Something meaningful to you about your AANHPI culture/identity
|
An example of Dr. Sandip Patel’s profile can be seen on Twitter, and more will be posted throughout the month. Please feel free to reach out to Maritza with any questions that you might have.
|
|
|
Behind the Science: A Cancer Research Forum
May 25, 2023 at 12:00 p.m.
Do you ever wonder what goes on at MCC? Join this webinar to get a look at the amazing things that MCC researchers are working on. From breast cancer to cannabis use among cancer patients to why cancers become drug resistant, MCC researchers are excited to share their science and discoveries. This forum is open to all in the community who want to learn more about cancer research, treatment, and prevention, especially at MCC. Please see the flyer linked below for more information.
|
|
|
Special Seminar: Lung Cancer Screening
June 7, 2023 at 12:00 p.m.
The MCC Cancer Control Research Program and MCC Community Outreach and Engagement invite you to a special seminar on lung cancer screening in San Diego. Although this will be a hybrid event, in-person attendance is preferred. Please see the flyer linked below for registration options and more information.
|
|
|
Summer Research Interns
MCC Cancer Research, Training, and Education Coordination (CRTEC) has a number of high school and undergraduate students who are looking to volunteer at MCC to do cancer-related research.
|
- 20-30 hours per week
- 4-6 weeks over the summer
|
This is a win-win: the students gain great experience, and your lab gains a highly motivated intern at no cost!
Please consider hosting a summer intern.
For more information, please contact Amy Spilkin, PhD at aspilkin@health.ucsd.edu
|
|
|
NCI Cancer Prevention Fellowship Program
Founded in 1987, the NCI Cancer Prevention Fellowship Program (CPFP) provides its fellows an opportunity to develop an independent research program in cancer prevention. The centerpiece of the program is mentored, multidisciplinary research. With input from senior scientists and program staff, each fellow develops original scientific projects and reports findings at meetings and in leading journals.
Applications for this program are open through August 1, 2023.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), Clinical Trial Award (CTA)
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot approximately $6.4M to fund one to three CTA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTA should not exceed $2.0M.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
| |
DOD OCRP Clinical Translational Research Award (CTRA)
The DOD CDMRP will allot approximately $3.2M to fund one to two CTRA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTRA should not exceed $2.0M.
The DOD CDMRP OCRP CTRA supports correlative studies that are associated with a clinical trial (past, ongoing, or future) to correlate various factors (genetic, biochemical, environmental, and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis, or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays and patient-derived models). The award may not be used to directly support a clinical trial.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
Integrating Health Disparities into Immuno-Oncology (HDIO) (P20 Clinical Trial Not Allowed), RFA-CA-23-038
This RFA will support planning and feasibility studies to integrate health disparity research into immuno-oncology studies. The P20 mechanism will enable complementary, multi-disciplinary research teams to address interdisciplinary research questions at the nexus of cancer disparities and cancer immunology. Proposed projects should feature novel or high-risk research hypotheses and lead to future submissions of well-integrated multi-disciplinary research project applications (e.g., P01s or R01s).
Questions can be directed to Tiffany A. Wallace, PhD at tiffany.wallace@nih.gov or Lillian S. Kuo, PhD at lillian.kuo@nih.gov.
LOI Deadline: May 30, 2023
|
|
|
Curebound: 2023 Letter of Intent Call for Discovery Grants, Targeted Grants, and Cure Prize
Discovery Grants are intended to fund high-risk high-reward innovative, collaborative research. The award provides $250,000 for a 1-year award inclusive of up to 30% IDC. Targeted Grants are intended to fund innovative, translational, oncology-based projects that show promise of advancing to pre-clinical or clinical stages. The award provides $500,000 for a 1- to 2-year award inclusive of up to 30% IDC. The Cure Prize is awarded to ground-breaking research projects that change the course of cancer research and care. The award provides $1,000,000 for a 2- to 3-year ward inclusive of up to 30% IDC.
Deadline: May 30, 2023
|
|
|
2023 Bayer-PCF Darolutamide Challenge Awards for Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer
Award provides up to a total of $1M per team. Approximately $3M is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards to fund novel investigator-initiated clinical investigations that address correlative research for darolutamide in prostate cancer. Proposals will be funded, depending on their level of innovation. PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
Application Submission Deadline: Monday, June 5, 2023 at 3:00 p.m. ET
|
|
|
Society for Immunotherapy of Cancer (SITC), 2023 Regular and Young Investigator Awards
Submit your ground-breaking research for consideration as an oral or poster abstract presentation at SITC 2023, the leading cancer immunotherapy and immunology conference. Regular and Young Investigator Award abstract submissions are being accepted through June 27, 2023 at 5:00 p.m. PT. SITC will offer 38 Young Investigator Awards, which recognize excellence in novel research and provide young investigators with the experience necessary for successful careers. All Young Investigator Award recipients will receive funds to assist with travel expenses for the upcoming 38th Annual SITC Meeting.
Deadline: June 27, 2023 at 5:00 p.m. PT
|
|
|
SITC Steven A. Rosenberg Scholars Award Call for Nominations
Established in 2020 in honor of Dr. Steven Rosenberg, this award recognizes and supports investigators who are emerging leaders in immuno-oncology. The recipient will receive $150,000 in research funding and will be recognized at the SITC 38th Annual Meeting Award Ceremony this November.
Deadline: July 15, 2023
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding; applications must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
| DOD Peer Reviewed Cancer Research Program (PRCRP) Impact Award
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot $17.6M to fund approximately 11 PRCRP Impact Award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP Impact Award should not exceed $1.0M.
Deadline: May 25, 2023
|
| Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
Application budgets may not exceed $250,000 in direct costs; maximum project length is 4 years.
Deadline: June 2, 2023
|
|
|
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: June 15, 2023
|
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
UG3: Application budgets may not exceed $250,000 in direct costs per year; maximum project period is 3 years.
UH3: Application budgets may not exceed $400,000 in direct costs per year; maximum project period is 2 years.
Deadline: June 30, 2023
|
|
|
Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
| DOD Lung Cancer, Patient-Centered Outcomes and Survivorship Award
The anticipated direct costs budgeted for the entire period of performance for an FY23 LCRP Patient-Centered Outcomes and Survivorship Award should not exceed $650,000.
Deadline: July 20, 2023
|
| DOD Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due date April 17, 2023.
Deadline: July 21, 2023
|
|
|
Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)
Application budgets are not limited; maximum project period is 5 years.
Deadline: July 24, 2023
|
| DOD PRCRP Translational Team Science Award (TTSA)
The DOD CDMRP will allot $36M to fund approximately nine PRCRP TTSA applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP TTSA should not exceed $2.5M.
Deadline: July 25, 2023
|
| DOD PRCRP Patient Well-Being and Survivorship Award (PWSA)
The DOD CDMRP will allot $6.4M to fund approximately four PRCRP PWSA award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP PWSA should not exceed $1.0M.
Deadline: July 25, 2023
|
|
|
DOD Lung Cancer Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10, 2023.
Deadline: August 3, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: September 1, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: September 1, 2023
|
|
|
NOSI: Career Development Opportunities for Research Supporting the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023 and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024.
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025.
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects to investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps laboratory investigates novel therapeutics for patients with leukemia and solid tumors. A particular focus of the laboratory is the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and that contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. These studies can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must possess a Ph.D., strong analytical skills, proficiency in oral and written scientific presentations, and a demonstrated commitment to a career in cancer research.
These postdoctoral positions are offered preferably to candidates who have recently received their Ph.D. or have completed 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three references to Beth Lipski at elipski@ucsd.edu.
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University website for updates.
|
|
|
MPN Advocacy and Education International, San Diego Patient and Caregiver Program
Thursday, May 25, 2023 from 9:00 a.m. to 2:00 p.m.
Manchester Grand Hyatt San Diego
1 Market Place San Diego, CA 92101
This program will provide updated information about myeloproliferative neoplasms, available support, treatment options, symptom management, pertinent information regarding stem cell transplants, among other topics. Meet with not only MPN patients and caregivers, but also MPN specialists who will be speaking in the program.
Speakers will include the following experts in the field:
|
- Dr. Catriona Jamieson, UC San Diego
- Dr. James Mangan, UC San Diego
- Dr. Raajit Rampal, Memorial Sloan Kettering Cancer Center
|
|
|
Moores Cancer Center Chicago Social
Attending the 2023 ASCO Annual Meeting? Join the MCC Chicago Social, hosted by MCC Director, Joseph Califano, MD on Sunday, June 4, 2023. RSVP for an evening of fun to enjoy top-notch drinks, bites, and sweeping views with MCC alumni, former colleagues, and current researchers, clinicians, physician-scientists, and trainees.
|
|
|
16th Annual Mechanisms and Models of Cancer Symposium
August 1 to August 4, 2023
Salk Institute, La Jolla, CA
Information, registration and submission can be found at the link below.
|
|
|
3rd Annual Race to Cure Sarcoma San Diego
Saturday, September 9, 2023 from 8:00 a.m. to 12:00 p.m.
Spanish Landing Park
The 3rd Annual Race to Cure Sarcoma San Diego will feature UC San Diego Orthopedic Oncologists Dr. James Flint (San Diego Race Coordinator and Team DryBones! Captain) and Dr. Frank Chiarappa (Team Chiarappa Captain). This race raises awareness for bone and soft tissue sarcoma, and half of the proceeds are returned to UC San Diego for sarcoma education and research. Please consider supporting UC San Diego-led teams or create your own team and join MCC in honoring its patients, families, physicians, providers, and supporters.
|
|
|
-
Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A (STT), et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 APR 01.
-
Jagadeeshan S, Prasad M, Badarni M, Ben-Lulu T, Liju VB, Mathukkada S, Saunders C, Shnerb AB, Zorea J, Yegodayev KM, Wainer M, Vtorov L, Allon I, Cohen O, Gausdal G, Friedmann-Morvinski D, Cheong SC, Ho AL, Rosenberg AJ, Kessler L, Burrows F, Kong D, Grandis JR, Gutkind JS (CBS), Elkabets M. Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer. Cancer Res. 2023 APR 04.
- Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, Dan YY, Roberts LR, Loomba R (CCP), Huang DQ. Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH. Hepatology. 2023 APR 01.
|
|
|
-
Research Assistant - Cancer Stem Cells - Thomas Kipps, MD Lab - Req #121358
-
Research Assistant - Novel Therapeutics - Stephen Howell, MD Lab - Req #121731
-
Research Associate - Histology - Alfredo Molinolo, PhD Lab - Req #121199
- Biorepository Research Associate - Req #11811
- Research Program Coordinator - Req #119931
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@health.ucsd.edu. To continue receiving our emails, add us to your address book.
|
|
|
|